YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.
Stock data | 2023 | Change |
---|---|---|
Price | $0.442 | N/A |
Market Cap | $41.13M | N/A |
Shares Outstanding | 93.06M | 0.96% |
Employees | 773.00 | N/A |
Shareholder Equity | 728.45M | -204.22% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -0.15 | N/A |
P/S Ratio | 0.42 | N/A |
P/B Ratio | 0.06 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.0282 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $96.97M | N/A |
Earnings | -$20.53M | N/A |
EPS | -3.05 | N/A |
Earnings Yield | -6.89 | N/A |
Gross Margin | 0.7768 | N/A |
Operating Margin | -0.1649 | N/A |
Net income margin | -0.2117 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $242.66M | N/A |
Total Debt | $70.36M | N/A |
Cash on Hand | $52.22M | N/A |
Debt to Equity | 0.1920 | -144.43% |
Cash to Debt | 0.7423 | 4.21% |
Current Ratio | $1.57 | -2.14% |